within Pharmacolibrary.Drugs.ATC.L;

model L01AA05
  extends Pharmacokinetic.Models.PK_2C(
    weight         = 70,
    F              = 1,
    Cl             = 4.166666666666667e-06,
    adminDuration  = 600,
    adminMass      = 0.4 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.0005,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,            
    Vdp             = 0.0002,
    k12             = 0.1,
    k21             = 0.1
    
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>L01AA05</td></tr><td>route:</td><td>intravenous</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Chlormethine (also known as mechlorethamine or nitrogen mustard) is an alkylating agent primarily used in the treatment of cancers such as Hodgkin lymphoma and cutaneous T-cell lymphoma. It is considered a cytotoxic chemotherapeutic agent. While systemic use has declined due to toxicity concerns and advent of newer agents, it remains approved and used today (notably as a topical formulation) for certain lymphomas.</p><h4>Pharmacokinetics</h4><p>Estimated pharmacokinetic parameters for intravenous administration in adult cancer patients based on classical nitrogen mustard literature, as no original detailed clinical PK publications are directly available for chlormethine (mechlorethamine).</p><h4>References</h4><ol><li><p>Dennie, TW, &amp; Kolesar, JM (2009). Bendamustine for the treatment of chronic lymphocytic leukemia and rituximab-refractory, indolent B-cell non-Hodgkin lymphoma. <i>Clinical therapeutics</i> 31 Pt 2 2290–2311. DOI:<a href=\"https://doi.org/10.1016/j.clinthera.2009.11.031\">10.1016/j.clinthera.2009.11.031</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/20110042/\">https://pubmed.ncbi.nlm.nih.gov/20110042</a></p></li><li><p>Dubbelman, AC, et al., &amp; Beijnen, JH (2012). Metabolite profiling of bendamustine in urine of cancer patients after administration of [14C]bendamustine. <i>Drug metabolism and disposition: the biological fate of chemicals</i> 40(7) 1297–1307. DOI:<a href=\"https://doi.org/10.1124/dmd.112.045229\">10.1124/dmd.112.045229</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/22492615/\">https://pubmed.ncbi.nlm.nih.gov/22492615</a></p></li><li><p>Chandra, B, et al., &amp; Palit, M (2020). Gas chromatography-tandem mass spectrometry-based detection of half nitrogen mustards in plasma as a new biomarker of nitrogen mustard exposure. <i>Analytical methods : advancing methods and applications</i> 12(36) 4447–4456. DOI:<a href=\"https://doi.org/10.1039/d0ay00916d\">10.1039/d0ay00916d</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/32856667/\">https://pubmed.ncbi.nlm.nih.gov/32856667</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end L01AA05;
